Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of narcolepsy
3.2.1.2 Introduction of novel therapeutic products, and advancements in R&D
3.2.1.3 Growing awareness and diagnosis
3.2.2 Industry pitfalls & challenges
3.2.2.1 Adverse effects and risks related to narcolepsy drugs
3.2.2.2 Delayed diagnosis or misdiagnosis
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Reimbursement scenario
3.6 Porter's analysis
3.7 PESTEL analysis
3.8 Future market trends
3.9 Gap analysis
3.10 Pipeline analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market player
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Narcolepsy with cataplexy (type 1)
5.3 Narcolepsy without cataplexy (type 2)
5.4 Secondary narcolepsy
Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Central nervous system stimulants
6.3 Sodium oxybate
6.4 Selective serotonin reuptake inhibitor
6.5 Tricyclic antidepressants
6.6 Histamine H3 receptor antagonists
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Retail pharmacies
7.3 Hospital pharmacies
7.4 Other pharmacies
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Italy
8.3.5 Spain
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Rest of Latin America
8.6 Middle East and Africa
8.6.1 Saudi Arabia
8.6.2 South Africa
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Avadel Pharmaceuticals
9.2 Axsome Therapeutics Inc.
9.3 Harmony Biosciences
9.4 Jazz Pharmaceuticals PLC
9.5 Mylan N.V.
9.6 Novartis AG
9.7 Rhodes Pharmaceuticals L.P.
9.8 Shionogi Inc.
9.9 Takeda Pharmaceutical Company
9.10 Teva Pharmaceuticals Industries Ltd
9.11 XWPharma Ltd.
